Melengestrol

DB11529

small molecule vet_approved

Deskripsi

Melengestrol is a steroidal progestin and antineoplastic agent which was never marketed. An acylated derivative, melengestrol acetate, is used as a growth promoter in animals.

Struktur Molekul 2D

Berat 354.49
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1040 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Melengestrol.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Melengestrol.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Melengestrol.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Melengestrol.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Melengestrol.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Melengestrol.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Melengestrol.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Melengestrol.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Melengestrol.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Melengestrol.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Melengestrol.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Melengestrol.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Melengestrol.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Melengestrol.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Melengestrol.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Melengestrol.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Melengestrol.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Melengestrol.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Melengestrol.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Melengestrol.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Melengestrol.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Melengestrol.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Melengestrol.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Melengestrol.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Melengestrol.
Cladribine Melengestrol may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Melengestrol.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Melengestrol.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Melengestrol.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Melengestrol.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Melengestrol.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Melengestrol.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Melengestrol.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Melengestrol.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Melengestrol.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Melengestrol.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Melengestrol.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Melengestrol.
Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Melengestrol.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Melengestrol.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Melengestrol.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Melengestrol.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Melengestrol.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Melengestrol.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Melengestrol.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Melengestrol.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Melengestrol.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Melengestrol.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Melengestrol.
Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Melengestrol.
Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Melengestrol.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Melengestrol.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Melengestrol.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Melengestrol.
Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Melengestrol.
Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Melengestrol.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Melengestrol.
Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Melengestrol.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Melengestrol.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Melengestrol.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Melengestrol.
Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Melengestrol.
Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Melengestrol.
Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Melengestrol.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Melengestrol.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Melengestrol.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Melengestrol.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Melengestrol.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Melengestrol.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Melengestrol.
Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Melengestrol.
Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Melengestrol.
Doxorubicin The risk or severity of adverse effects can be increased when Doxorubicin is combined with Melengestrol.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Melengestrol.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Melengestrol.
Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Melengestrol.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Melengestrol.
Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Melengestrol.
Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Melengestrol.
Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Melengestrol.
Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Melengestrol.
Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Melengestrol.
Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Melengestrol.
Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Melengestrol.
Idarubicin The risk or severity of adverse effects can be increased when Idarubicin is combined with Melengestrol.
Ifosfamide The risk or severity of adverse effects can be increased when Ifosfamide is combined with Melengestrol.
Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Melengestrol.
Mitoxantrone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Melengestrol.
Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Melengestrol.
Docetaxel The risk or severity of adverse effects can be increased when Docetaxel is combined with Melengestrol.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Melengestrol.
Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Melengestrol.
Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Melengestrol.
Stepronin The risk or severity of adverse effects can be increased when Stepronin is combined with Melengestrol.
Hydroxychloroquine The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Melengestrol.
Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Melengestrol.
Vorinostat The risk or severity of adverse effects can be increased when Vorinostat is combined with Melengestrol.
2-Methoxyethanol The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Melengestrol.
Brequinar The risk or severity of adverse effects can be increased when Brequinar is combined with Melengestrol.
Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Melengestrol.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 327640
    Kountz SL, Wechter WJ: Immunosuppression with melengestrol. Transplant Proc. 1977 Jun;9(2):1447-53.
  • PMID: 6049897
    Cooper JM, Elce JS, Kellie AE: The metabolism of melengestrol acetate. Biochem J. 1967 Sep;104(3):57P-58P.
  • PMID: 14192473
    DUNCAN GW, LYSTER SC, HENDRIX JW, CLARK JJ, WEBSTER HD: BIOLOGIC EFFECTS OF MELENGESTROL ACETATE. Fertil Steril. 1964 Jul-Aug;15:416-32.
  • PMID: 5465999
    Pritchard DE, Wettemann RP, Hafs HD: Fertility of rabbits after melengestrol acetate administration. J Anim Sci. 1970 Oct;31(4):729-32.
  • PMID: 4495779
    Herrick JB: Answers to questions about MGA (melengestrol acetate). Vet Med Small Anim Clin. 1974 Aug;69(8):1040-2.
  • PMID: 4781045
    Krzeminski LF, Cox BL: Electron capture determination of melengestrol acetate in bovine tissue. J Assoc Off Anal Chem. 1973 Jan;56(1):74-6.
  • PMID: 1270378
    Krzeminski LF, Geng S, Cox BL: Determination of melengestrol acetate in bovine tissue: collaborative study. J Assoc Off Anal Chem. 1976 May;59(3):507-15.
  • PMID: 1100303
    Nugent CA, Bressler R, Kayan S, Worrall P: Suppression of cortisol by a progestational steroid, melengestrol. Clin Pharmacol Ther. 1975 Sep;18(3):338-44.
Menampilkan 8 dari 10 artikel.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul